Table 2: Sustained viral response status by genotype and treatment regimen.
| Regimen | No. (%) of patients | p value | |
|---|---|---|---|
| Achieved SVR n = 326 |
Did not achieve SVR n = 25 |
||
| Genotype 1a (n = 206) | 193 (93.7) | 13 (6.3) | 0.5 |
| Sofosbuvir-ledipasvir (n = 158) | 147 (93.0) | 11 (7.0) | |
| Sofosbuvir-ledipasvir + ribavirin (n = 13) | 12 (92.3) | 1 (7.7) | |
| Simeprevir-sofosbuvir (n = 17) | 17 (100.0) | 0 (0.0) | 0.8 |
| Pegylated interferon + direct-acting antiviral (n = 13) | 12 (92.3) | 1 (7.7) | |
| Ombitasvir-paritaprevir-ritonavir and dasabuvir ± ribavirin (n = 5) | 5 (100.0) | 0 (0.0) | |
| Genotype 1b (n = 59) | 57 (96.6) | 2 (3.4) | 0.2 |
| Sofosbuvir-ledipasvir (n = 48) | 46 (95.8) | 2 (4.2) | |
| Sofosbuvir-ledipasvir + ribavirin (n = 1) | 1 (100.0) | 0 (0.0) | |
| Simeprevir-sofosbuvir (n = 2) | 2 (100.0) | 0 (0.0) | 1.0 |
| Pegylated interferon + direct-acting antiviral (n = 3) | 3 (100.0) | 0 (0.0) | |
| Ombitasvir-paritaprevir-ritonavir and dasabuvir ± ribavirin (n = 5) | 5 (100.0) | 0 (0.0) | |
| Genotype 2 (n = 25) | 22 (88.0) | 3 (12.0) | 0.4 |
| Sofosbuvir + ribavirin (n = 23) | 20 (87.0) | 3 (13.0) | |
| Pegylated interferon + direct-acting antiviral (n = 2) | 2 (100.0) | 0 (0.0) | |
| Genotype 3 (n = 51) | 44 (86.3) | 7 (13.7) | 0.1 |
| Sofosbuvir-ledipasvir + ribavirin (n = 1) | 1 (100.0) | 0 | |
| Sofosbuvir + ribavirin (n = 45) | 38 (84.4) | 7 (15.6) | |
| Pegylated interferon + direct-acting antiviral (n = 5) | 5 (100.0) | 0 (0.0) | |
| Other (n = 9) | 9 (100.0) | 0 (0.0) | 1.0 |
| Sofosbuvir-ledipasvir (n = 4) | 4 (100.0) | 0 (0.0) | |
| Sofosbuvir-ledipasvir + ribavirin (n = 1) | 1 (100.0) | 0 (0.0) | |
| Sofosbuvir + ribavirin (n = 2) | 2 (100.0) | 0 (0.0) | 1.0 |
| Pegylated interferon + direct-acting antiviral (n = 1) | 1 (100.0) | 0 (0.0) | |
| Ombitasvir-paritaprevir-ritonavir and dasabuvir ± ribavirin (n = 1) | 1 (100.0) | 0 (0.0) | |
Note: SVR = sustained viral response.